Aim­mune signs Jayson Dal­las on to suc­ceed re­tir­ing CEO; Ed­uar­do Bra­vo leaves TiGenix in fi­nal chap­ter of Take­da buy­out

→ Ex-Ul­tragenyx com­mer­cial chief Jayson Dal­las is tak­ing the helm at Aim­mune Ther­a­peu­tics $AIMT — the com­pa­ny best known for its peanut al­ler­gy drug — well in time for a com­fort­able tran­si­tion with the out­go­ing CEO, Stephen Dil­ly. Dur­ing his three-year stint at Ul­tragenyx, Dal­las built up the com­mer­cial op­er­a­tions, in­clud­ing sales, mar­ket­ing, re­im­burse­ment and new prod­uct plan­ning, lead­ing up to the launch of the its first two rare dis­ease prod­ucts, which both won ap­proval last year. This marks his sec­ond job at a biotech, af­ter cut­ting his teeth at Pfiz­er, No­var­tis and then Roche/Genen­tech. He will now work on reg­u­la­to­ry fil­ings for AR101 with Dil­ly, who’s stay­ing on as a spe­cial ad­vis­er un­til the end of the year. Dil­ly an­nounced last No­vem­ber that he’s re­tir­ing to spend more time with fam­i­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.